Servier Pharmaceuticals shared a post on LinkedIn:
“2026 Golden Ticket applications are still open!
We’re looking for early-stage biotech start-ups in the Boston area advancing innovative therapies in oncology, neurology, or focusing on AI and enabling technologies in those fields. The winning start-up will receive access to lab space at LabCentral in Cambridge, MA, mentorship and guidance from Servier experts, and a $50,000 credit toward LabCentral services.
At Servier, we believe that early-stage collaborations are key to accelerating science and bringing new therapies to patients. This is your chance to join a community of innovators and fast-track your R&D projects!
Submit your non-confidential pitch deck here before March 2.”
More posts featuring Servier Pharmaceuticals on OncoDaily.